| Title |
Advances in the use of topical imiquimod to treat dermatologic disorders
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, February 2008
|
| DOI | 10.2147/tcrm.s1109 |
| Pubmed ID | |
| Authors |
Francesco Lacarrubba, Maria Rita Nasca, Giuseppe Micali |
| Abstract |
Imiquimod (IQ) is an immune-response modifying agent, first approved by FDA for the topical treatment of external genital and perianal warts in 1997. It induces, through stimulation of Toll-like receptors (TLRs) localized on the surface of antigen-presenting cells, synthesis and release of several endogenous pro-inflammatory cytokines such as interferon-alpha (IFN-alpha), tumor necrosis factor-alpha (TNF-alpha) and interleukins (IL) 6 and 12, which in turn stimulate both the innate and acquired immune pathways, resulting in upregulation of natural antiviral and antitumor activity. IQ 5% cream has been used for the treatment of a wide variety of dermatologic conditions in which the immune system is thought to play a role in regression of the disease. In some disorders, such as genital and perianal warts, actinic keratoses, basal cell carcinomas, Bowen's disease and molluscum contagiosum, relative safety and efficacy are supported by randomized controlled trials of IQ. However, it is common for patients to experience local skin reactions, which can range from mild to severe in intensity, but usually resolve 1-2 weeks after interrupting treatment. Additional randomized trials are encouraged to assess safety and efficacy of IQ in the treatment of an even wider range of cutaneous disorders. |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 1 | 2% |
| Unknown | 42 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 8 | 19% |
| Student > Doctoral Student | 6 | 14% |
| Researcher | 6 | 14% |
| Student > Master | 5 | 12% |
| Student > Bachelor | 3 | 7% |
| Other | 3 | 7% |
| Unknown | 12 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 37% |
| Agricultural and Biological Sciences | 4 | 9% |
| Immunology and Microbiology | 3 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Other | 1 | 2% |
| Unknown | 15 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 September 2018.
All research outputs
#8,534,976
of 25,373,627 outputs
Outputs from Therapeutics and Clinical Risk Management
#461
of 1,323 outputs
Outputs of similar age
#46,815
of 172,948 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#16
of 21 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,948 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.